SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and Iceland.
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Beautiful colorful unpeeled peanut pattern on a light blue background. Flat lay arrangement, top view.
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children with one or more food allergies.
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Human Nose Like Worker Is Going To Work. Vector Collage Illustration Against The Background Of The City
Immunology and inflammation
AstraZeneca, Amgen’s Phase III Win Strengthens Case for Tezspire Expansion
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the first half of 2025.
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Drug Development
The Chilling Effect: State Actions, Patient Data Vulnerability, and DEI Uncertainty
In the current legal and political landscape, it is all about survival for DEI initiatives.
March 3, 2025
 · 
1 min read
Balance. Sphere. Scale. 3d illustration.
Obesity
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate an evolving mindset toward treating obesity as a chronic disease.
March 3, 2025
 · 
7 min read
 · 
Kate Goodwin
Rear view businessman in front of many different doors choosing one. Difficult decision, important choice, failure or success concept. Decisive ways to unknown future, business opportunity symbol.
Cancer
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a crossroads, with experts highlighting novel targets, combinations and pre-emptive immunization as the next wave for IO.
March 3, 2025
 · 
7 min read
 · 
Heather McKenzie
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
In the five weeks since Donald Trump returned as U.S. president, the FDA, NIH and CDC have been thrown into disarray, with meetings regarding vaccines and rare diseases canceled or indefinitely postponed—all without a clear reason why.
February 28, 2025
 · 
4 min read
 · 
Heather McKenzie
Creative background
Deals
BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal
In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix Acquisition Corp. II worth $450 million in proceeds.
February 28, 2025
 · 
2 min read
 · 
Annalee Armstrong
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American headquarters in Nutley, New Jersey. A company spokesperson said the pharma remains fully committed to the U.S. market.
February 28, 2025
 · 
1 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS